Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...
In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...
Traditional drug development methods involve identifying a target protin (e.g., a cancer cell receptor) that causes disease, and then searching through countless molecular candidates (potential drugs) ...
KAIST (President Kwang Hyung Lee) announced on the 10th that a research team led by Professor Woo Youn Kim in the Department of Chemistry has developed an AI model named BInD (Bond and ...
Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins
Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...
Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results